Although it has been more than 200 years since Parkinson's disease was described, we have not established biomarkers for its definitive diagnosis yet. Moreover, there is a similar case for the entire group of α-synucleinopathies, which are all characterized by the pathological accumulation of aggregated α-synuclein (α-Syn) in the brain and other tissues. In different biological materials (blood, cerebrospinal fluid, saliva, or skin), α-Syn exists in various conformations and various aggregated states depending on the surrounding environment. Lewy bodies have been considered a pathognomonic feature of Parkinson's disease for over 100 years, and α-Syn has been known to be a key component of Lewy bodies for over 25 years, making it possible to confirm the diagnosis by post-mortem examination of brain tissue. To overcome these limitations, novel analytical seed amplification assays (SAAs) were introduced, and they quickly became one of the most effective diagnostic tools for antemortem detection of α-synucleinopathies. As they require minimal sample amounts to provide consistent, rapid, and reliable results, SAAs are ideally suited for biomarker determination. This review examines SAA analytical and detection methods, their advantages and strengths, as well as their limitations and shortcomings that need to be addressed to establish a reliable and reproducible protocol. This could serve as a diagnostic methodology worldwide to determine the presence of pathological α-Syn protein at early stages and help develop effective disease-modifying treatment.

Department of Molecular Pathology Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Department of Neurology Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Department of Neurology Santa Maria University Hospital Terni Italy

Department of Neurology University Hospital Olomouc Olomouc Czechia

Laboratory of Growth Regulators Institute of Experimental Botany of the Czech Academy of Sciences and Palacky University Olomouc Czechia

Olomouc Brain Bank Department of Neurology and Department of Clinical and Molecular Pathology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc Czechia

Erratum v

Front Neurol. 2025 Jun 09;16:1636086. doi: 10.3389/fneur.2025.1636086. PubMed

Zobrazit více v PubMed

Hatano T, Okuzumi A, Matsumoto G, Tsunemi T, Hattori N. α-Synuclein: a promising biomarker for Parkinson’s disease and related disorders. J Mov Disord. (2024) 17:127–37. doi: 10.14802/jmd.24075, PMID: PubMed DOI PMC

Meade RM, Fairlie DP, Mason JM. Alpha-synuclein structure and Parkinson’s disease- lessons and emerging principles. Mol Neurodegener. (2019) 14:29. doi: 10.1186/s13024-019-0329-1, PMID: PubMed DOI PMC

Bisi N, Feni L, Peqini K, Pérez-Peña H, Ongeri S, Pieraccini S, et al. α-Synuclein: an all-inclusive trip around its structure, influencing factors and applied techniques. Front Chem. (2021) 9:666585. doi: 10.3389/fchem.2021.666585, PMID: PubMed DOI PMC

Soto C. α-Synuclein seed amplification technology for Parkinson’s disease and related synucleinopathies. Trends Biotechnol. (2024) 42:829–41. doi: 10.1016/j.tibtech.2024.01.007, PMID: PubMed DOI PMC

Mehra S, Gadhe L, Bera R, Sawner AS, Maji SK. Structural and functional insights into α-synuclein fibril polymorphism. Biomol Ther. (2021) 11:1419. doi: 10.3390/biom11101419, PMID: PubMed DOI PMC

Vascellari S, Orrù CD, Caughey B. Real-time quaking- induced conversion assays for prion diseases, synucleinopathies, and tauopathies. Front Aging Neurosci. (2022) 14:853050. doi: 10.3389/fnagi.2022.853050, PMID: PubMed DOI PMC

Froula JM, Castellana-Cruz M, Anabtawi NM, Camino JD, Chen SW, Thrasher DR, et al. Defining α-synuclein species responsible for Parkinson’s disease phenotypes in mice. J Biol Chem. (2019) 294:10392–406. doi: 10.1074/jbc.RA119.007743, PMID: PubMed DOI PMC

Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy. Nature. (2020) 578:273–7. doi: 10.1038/s41586-020-1984-7, PMID: PubMed DOI PMC

Schaeffer E, Kluge A, Schulte C, Deuschle C, Bunk J, Welzel J, et al. Association of misfolded α-synuclein derived from neuronal exosomes in blood with Parkinson’s disease diagnosis and duration. J Parkinsons Dis. (2024) 14:667–79. doi: 10.3233/JPD-230390, PMID: PubMed DOI PMC

Bentivenga GM, Mammana A, Baiardi S, Rossi M, Ticca A, Magliocchetti F, et al. Performance of a seed amplification assay for misfolded alpha-synuclein in cerebrospinal fluid and brain tissue in relation to Lewy body disease stage and pathology burden. Acta Neuropathol. (2024) 147:18. doi: 10.1007/s00401-023-02663-0, PMID: PubMed DOI PMC

Mahul-Mellier AL, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F, et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci USA. (2020) 117:4971–82. doi: 10.1073/pnas.1913904117, PMID: PubMed DOI PMC

Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. (2003) 24:197–211. doi: 10.1016/s0197-4580(02)00065-9 PubMed DOI

Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. (2004) 318:121–34. doi: 10.1007/s00441-004-0956-9, PMID: PubMed DOI

Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, et al. Staging/typing of Lewy body related alpha-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol. (2009) 117:635–52. doi: 10.1007/s00401-009-0523-2, PMID: PubMed DOI

Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance. Acta Neuropathol. (2008) 115:399–407. doi: 10.1007/s00401-008-0346-6, PMID: PubMed DOI PMC

Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. MRC cognitive function, ageing neuropathology study. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology. (2008) 70:1042–8. doi: 10.1212/01.wnl.0000306697.48738.b6 PubMed DOI

Sorrentino ZA, Goodwin MS, Riffe CJ, Dhillon JS, Xia Y, Gorion KM, et al. Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. Acta Neuropathol Commun. (2019) 7:142. doi: 10.1186/s40478-019-0787-2, PMID: PubMed DOI PMC

Concha-Marambio L, Pritzkow S, Shahnawaz M, Farris CM, Soto C. Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid. Nat Protoc. (2023) 18:1179–96. doi: 10.1038/s41596-022-00787-3, PMID: PubMed DOI PMC

Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, et al. Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med. (2023) 29:1448–55. doi: 10.1038/s41591-023-02358-9, PMID: PubMed DOI PMC

Bargar C, Wang W, Gunzler SA, LeFevre A, Wang Z, Lerner AJ, et al. Streamlined alpha-synuclein RT-QuIC assay for various biospecimens in Parkinson’s disease and dementia with Lewy bodies. Acta Neuropathol Commun. (2021) 9:62. doi: 10.1186/s40478-021-01175-w, PMID: PubMed DOI PMC

Scott GD, Arnold MR, Beach TG, Gibbons CH, Kanthasamy AG, Lebovitz RM, et al. Fluid and tissue biomarkers of Lewy body dementia: report of an LBDA symposium. Front Neurol. (2022) 12:805135. doi: 10.3389/fneur.2021.805135, PMID: PubMed DOI PMC

Mammana A, Baiardi S, Rossi M, Quadalti C, Ticca A, Magliocchetti F, et al. Improving protocols for α-synuclein seed amplification assays: analysis of preanalytical and analytical variables and identification of candidate parameters for seed quantification. Clin Chem Lab Med. (2024) 62:2001–10. doi: 10.1515/cclm-2023-1472, PMID: PubMed DOI

Brockmann K, Lerche S, Baiardi S, Rossi M, Wurster I, Quadalti C, et al. CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease. npj Parkinsons Dis. (2024) 10:24. doi: 10.1038/s41531-023-00627-5, PMID: PubMed DOI PMC

Bernhardt AM, Longen S, Trossbach SV, Rossi M, Weckbecker D, Schmidt F, et al. A quantitative Lewy-fold-specific alpha-synuclein seed amplification assay as a progression marker for Parkinson’s disease. Acta Neuropathol. (2025) 149:20. doi: 10.1007/s00401-025-02853-y, PMID: PubMed DOI PMC

Chu Y, Kordower JH. The prion hypothesis of Parkinson’s disease. Curr Neurol Neurosci Rep. (2015) 15:28. doi: 10.1007/s11910-015-0549-x, PMID: PubMed DOI

Poggiolini I, Gupta V, Lawton M, Lee S, El-Turabi A, Querejeta-Coma A, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies. Brain. (2022) 145:584–95. doi: 10.1093/brain/awab431, PMID: PubMed DOI PMC

Groveman BR, Orrù CD, Hughson AG, Raymond LD, Zanusso G, Ghetti B, et al. Rapid and ultra-sensitive quantitation of disease-associated α-synuclein seeds in brain and cerebrospinal fluid by αSyn RT-QuIC. Acta Neuropathol Commun. (2018) 6:7. doi: 10.1186/s40478-018-0508-2, PMID: PubMed DOI PMC

Schmitz M, Candelise N, Canaslan S, Altmeppen HC, Matschke J, Glatzel M, et al. α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies. Transl Neurodegener. (2023) 12:12. doi: 10.1186/s40035-023-00342-4, PMID: PubMed DOI PMC

Ferreira N, Gram H, Sorrentino ZA, Gregersen E, Schmidt SI, Reimer L, et al. Multiple system atrophy-associated oligodendroglial protein p25α stimulates formation of novel α-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathol. (2021) 142:87–115. doi: 10.1007/s00401-021-02316-0, PMID: PubMed DOI PMC

Wang Q, Luo Y, Ray Chaudhuri K, Reynolds R, Tan EK, Pettersson S. The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options. Brain. (2021) 144:2571–93. doi: 10.1093/brain/awab156, PMID: PubMed DOI

Morris HR, Lees AJ. Limitations of the α-synuclein seed amplification assay in clinical practice: understanding the pathological diversity of Parkinson syndrome. JAMA Neurol. (2024) 81:905. doi: 10.1001/jamaneurol.2024.2381 PubMed DOI

Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, et al. Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. (2023) 22:407–17. doi: 10.1016/S1474-4422(23)00109-6, PMID: PubMed DOI PMC

Berg D, Klein C. α-Synuclein seed amplification and its uses in Parkinson’s disease. Lancet Neurol. (2023) 22:369–71. doi: 10.1016/S1474-4422(23)00124-2, PMID: PubMed DOI

Abdi IY, Hashish SA, El-Agnaf OA. Seeding amplification assay: limitations and insights for enhanced clinical and research applications. J Parkinsons Dis. (2025) 2:1877718X251325124. doi: 10.1177/1877718X251325124, PMID: PubMed DOI

Dong TT, Satoh K. The latest research on RT-QuIC assays—a literature review. Pathogens. (2021) 10:305. doi: 10.3390/pathogens10030305, PMID: PubMed DOI PMC

Collins SR, Douglass A, Vale RD, Weissman JS. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. (2004) 2:e321. doi: 10.1371/journal.pbio.0020321, PMID: PubMed DOI PMC

Orrù CD, Ma TC, Hughson AG, Groveman BR, Srivastava A, Galasko D, et al. A rapid α-synuclein seed assay of Parkinson’s disease CSF panel shows high diagnostic accuracy. Ann Clin Transl Neurol. (2021) 8:374–84. doi: 10.1002/acn3.51280, PMID: PubMed DOI PMC

Shahnawaz M, Tokuda T, Waragai M, Mendez N, Ishii R, Trenkwalder C, et al. Development of a biochemical diagnosis of Parkinson disease by detection of α-synuclein misfolded aggregates in cerebrospinal fluid. JAMA Neurol. (2017) 74:163–72. doi: 10.1001/jamaneurol.2016.4547, PMID: PubMed DOI

Huang J, Yuan X, Chen L, Hu B, Wang H, Wang Y, et al. Pathological α-synuclein detected by real-time quaking-induced conversion in synucleinopathies. Exp Gerontol. (2024) 187:112366. doi: 10.1016/j.exger.2024.112366, PMID: PubMed DOI

Wang Z, Gilliland T, Kim HJ, Gerasimenko M, Sajewski K, Camacho MV, et al. A minimally invasive biomarker for sensitive and accurate diagnosis of Parkinson’s disease. Acta Neuropathol Commun. (2024) 12:167. doi: 10.1186/s40478-024-01873-1, PMID: PubMed DOI PMC

De Luca CMG, Elia AE, Portaleone SM, Cazzaniga FA, Rossi M, Bistaffa E, et al. Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy. Transl Neurodegener. (2019) 8:24. doi: 10.1186/s40035-019-0164-x, PMID: PubMed DOI PMC

Li J, Duan S, Yang J, Zheng H, Yuan Y, Tang M, et al. Detection of skin α-synuclein using RT-QuIC as a diagnostic biomarker for Parkinson’s disease in the Chinese population. Eur J Med Res. (2024) 29:114. doi: 10.1186/s40001-024-01705-x, PMID: PubMed DOI PMC

Kuzkina A, Bargar C, Schmitt D, Rößle J, Wang W, Schubert AL, et al. Diagnostic value of skin RT-QuIC in Parkinson’s disease: a two-laboratory study. npj Parkinsons Dis. (2021) 7:99. doi: 10.1038/s41531-021-00242-2, PMID: PubMed DOI PMC

Ma Q, Ineichen BV, Detmar M, Proulx ST. Outflow of cerebrospinal fluid is predominantly through lymphatic vessels and is reduced in aged mice. Nat Commun. (2017) 8:1434. doi: 10.1038/s41467-017-01484-6, PMID: PubMed DOI PMC

Perra D, Bongianni M, Novi G, Janes F, Bessi V, Capaldi S, et al. Alpha-synuclein seeds in olfactory mucosa and cerebrospinal fluid of patients with dementia with Lewy bodies. Brain Commun. (2021) 3:fcab045. doi: 10.1093/braincomms/fcab045, PMID: PubMed DOI PMC

Bongianni M, Catalan M, Perra D, Fontana E, Janes F, Bertolotti C, et al. Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease. Transl Neurodegener. (2022) 11:37. doi: 10.1186/s40035-022-00311-3, PMID: PubMed DOI PMC

Manca M, Kraus A. Defining the protein seeds of neurodegeneration using real-time quaking-induced conversion assays. Biomol Ther. (2020) 10:1233. doi: 10.3390/biom10091233, PMID: PubMed DOI PMC

Tuominen RK, Renko JM. Biomarkers of Parkinson’s disease in perspective of early diagnosis and translation of neurotrophic therapies. Basic Clin Pharmacol Toxicol. (2024) 135:271–84. doi: 10.1111/bcpt.14042, PMID: PubMed DOI

Srivastava A, Wang Q, Orrù CD, Fernandez M, Compta Y, Ghetti B, et al. Enhanced quantitation of pathological α-synuclein in patient biospecimens by RT-QuIC seed amplification assays. PLoS Pathog. (2024) 20:e1012554. doi: 10.1371/journal.ppat.1012554, PMID: PubMed DOI PMC

Lee SS, Civitelli L, Parkkinen L. Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles. eLife. (2024) 13:RP92775. doi: 10.7554/eLife.92775, PMID: PubMed DOI PMC

Painous C, Fernández M, Pérez J, de Mena L, Cámara A, Compta Y. Fluid and tissue biomarkers in Parkinson’s disease: immunodetection or seed amplification? Central or peripheral? Parkinsonism Relat Disord. (2024) 121:105968. doi: 10.1016/j.parkreldis.2023.105968, PMID: PubMed DOI

Espay AJ, Lees AJ, Cardoso F, Frucht SJ, Erskine D, Sandoval IM, et al. The α-synuclein seed amplification assay: interpreting a test of Parkinson’s pathology. Parkinsonism Relat Disord. (2025) 131:107256. doi: 10.1016/j.parkreldis.2024.107256, PMID: PubMed DOI

Grossauer A, Hemicker G, Krismer F, Peball M, Djamshidian A, Poewe W, et al. α-Synuclein seed amplification assays in the diagnosis of synucleinopathies using cerebrospinal fluid—a systematic review and meta-analysis. Mov Disord Clin Pract. (2023) 10:737–47. doi: 10.1002/mdc3.13710, PMID: PubMed DOI PMC